Search

Your search keyword '"Reyal, Fabien"' showing total 877 results
Start Over Author "Reyal, Fabien"
877 results on '"Reyal, Fabien"'

1. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective.

Author

Gougis, Paul, Jochum, Floriane, Abbar, Baptiste, Dumas, Elise, Bihan, Kevin, Lebrun-Vignes, Bénédicte, Moslehi, Javid, Spano, Jean-Philippe, Laas, Enora, Hotton, Judicael, Reyal, Fabien, Hamy, Anne-Sophie, and Salem, Joe-Elie

Subjects
Cancer, Fatal, Immune checkpoint inhibitors, Immune-related adverse events, Myotoxicity, Pharmacology, Pharmacovigilance
Abstract

BACKGROUND: Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment by harnessing the immune system but ICI can induce life-threatening immune-related adverse events (irAE) affecting every organ. METHODS: We extracted irAE from VigiBase, the international pharmacovigilance database, first reported in 2008 until 01/2023 to characterize irAE reporting trends, clinical features, risk factors and outcomes. FINDINGS: We distinguished 25 types of irAE (n = 50,347cases, single irAE/case in 84.9%). Cases mainly involved anti-PD1 (programmed-death-1) monotherapy (62.4%) in male (61.7%) aged 64.3 ± 12.6 years. After 2020 vs. prior to 2016, proportion of anti-CTLA4 (Cytotoxic-T-Lymphocyte-Antigen-4) monotherapy prescription almost vanished (1.6% vs. 47%, respectively) contrasting with increased use of anti-PDL1 (PD1-ligand) monotherapy (18% vs. 0.9%) and anti-CTLA4+anti-PD(L)1 combination (20% vs. 8.9%). Anti-LAG3 (Lymphocyte-Activation-Gene-3) prescription was limited (5) were presence of thymic cancer for ICI-myotoxicities or hepatitis; presence of melanoma for vitiligo, uveitis or sarcoidosis; specific types of ICI regimen (anti-LAG3 for meningitis, anti-CTLA4 for hypophysitis); and specific reporting regions (eastern Asia for cholangitis). Median time-to-onset ranged from 31 to 273 days, being shortest for myotoxicities and most delayed for skin-bullous auto-immune reactions. Overall fatality was highest for myocarditis = 27.6%, myasthenia = 23.1%, severe cutaneous adverse reactions (SCAR) = 22.1%, myositis = 21.9%, pneumonitis = 21%, and encephalomyelitis = 18%; generally decreasing after 2020, except for myasthenia and SCAR. When reported, irAE recurrence rate after rechallenge was 28.9% (n = 275/951). INTERPRETATION: This up-to-date comprehensive worldwide pharmacovigilance study defines the spectrum, characteristics, and evolution of irAE reporting summarizing over a decade of use. Multiple risk factors and clinical peculiarities for specific irAE have been identified as signals to guide clinical practice and future research. FUNDING: Paul Gougis was supported by the academic program: Contrats ED: Programme blanc Institut Curie PSL for the conduct of his PhD. Baptiste Abbar was supported by the Fondation ARC Pour le Rechercher Sur le Cancer. The RT2L research group (Institut Curie) was supported by the academic program SHS INCa, Sanofi iTech award, and by Monoprix∗.

Published
2024

2. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses

Author

Wang, Menglin, Rousseau, Benoit, Qiu, Kunyu, Huang, Guannan, Zhang, Yu, Su, Hang, Le Bihan-Benjamin, Christine, Khati, Ines, Artz, Oliver, Foote, Michael B., Cheng, Yung-Yi, Lee, Kuo-Hsiung, Miao, Michael Z., Sun, Yue, Bousquet, Philippe-Jean, Hilmi, Marc, Dumas, Elise, Hamy, Anne-Sophie, Reyal, Fabien, Lin, Lin, Armistead, Paul M., Song, Wantong, Vargason, Ava, Arthur, Janelle C., Liu, Yun, Guo, Jianfeng, Zhou, Xuefei, Nguyen, Juliane, He, Yongqun, Ting, Jenny P.-Y., Anselmo, Aaron C., and Huang, Leaf

Published
2024
Full Text
View/download PDF

3. Concomitant medication, comorbidity and survival in patients with breast cancer

Author

Dumas, Elise, Grandal Rejo, Beatriz, Gougis, Paul, Houzard, Sophie, Abécassis, Judith, Jochum, Floriane, Marande, Benjamin, Ballesta, Annabelle, Del Nery, Elaine, Dubois, Thierry, Alsafadi, Samar, Asselain, Bernard, Latouche, Aurélien, Espie, Marc, Laas, Enora, Coussy, Florence, Bouchez, Clémentine, Pierga, Jean-Yves, Le Bihan-Benjamin, Christine, Bousquet, Philippe-Jean, Hotton, Judicaël, Azencott, Chloé-Agathe, Reyal, Fabien, and Hamy, Anne-Sophie

Published
2024
Full Text
View/download PDF

5. EDEN : An Event DEtection Network for the annotation of Breast Cancer recurrences in administrative claims data

Author

Dumas, Elise, Hamy, Anne-Sophie, Houzard, Sophie, Hernandez, Eva, Toussaint, Aullène, Guerin, Julien, Chanas, Laetitia, de Castelbajac, Victoire, Saint-Ghislain, Mathilde, Grandal, Beatriz, Daoud, Eric, Reyal, Fabien, and Azencott, Chloé-Agathe

Subjects
Computer Science - Machine Learning
Abstract

While the emergence of large administrative claims data provides opportunities for research, their use remains limited by the lack of clinical annotations relevant to disease outcomes, such as recurrence in breast cancer (BC). Several challenges arise from the annotation of such endpoints in administrative claims, including the need to infer both the occurrence and the date of the recurrence, the right-censoring of data, or the importance of time intervals between medical visits. Deep learning approaches have been successfully used to label temporal medical sequences, but no method is currently able to handle simultaneously right-censoring and visit temporality to detect survival events in medical sequences. We propose EDEN (Event DEtection Network), a time-aware Long-Short-Term-Memory network for survival analyses, and its custom loss function. Our method outperforms several state-of-the-art approaches on real-world BC datasets. EDEN constitutes a powerful tool to annotate disease recurrence from administrative claims, thus paving the way for the massive use of such data in BC research., Comment: Extended Abstract presented at Machine Learning for Health (ML4H) symposium 2022, November 28th, 2022, New Orleans, United States & Virtual, http://www.ml4h.cc, 6 pages

Published
2022

6. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy

Author

Malhaire, Caroline, Selhane, Fatine, Saint-Martin, Marie-Judith, Cockenpot, Vincent, Akl, Pia, Laas, Enora, Bellesoeur, Audrey, Ala Eddine, Catherine, Bereby-Kahane, Melodie, Manceau, Julie, Sebbag-Sfez, Delphine, Pierga, Jean-Yves, Reyal, Fabien, Vincent-Salomon, Anne, Brisse, Herve, and Frouin, Frederique

Published
2023
Full Text
View/download PDF

8. Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial

Author

Giacchetti, Sylvie, Laas, Enora, Bachelot, Thomas, Lemonnier, Jérome, André, Fabrice, Cameron, David, Bliss, Judith, Chabaud, Sylvie, Hardy- Bessard, Anne-Claire, Lacroix-Triki, Magali, Canon, Jean-Luc, Debled, Marc, Campone, Mario, Cottu, Paul, Dalenc, Florence, Ballesta, Annabelle, Penault-Llorca, Frederique, Asselain, Bernard, Dumas, Elise, Reyal, Fabien, Gougis, Paul, Lévi, Francis, and Hamy, Anne-Sophie

Published
2024
Full Text
View/download PDF

9. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

Author

ter Brugge, Petra, Moser, Sarah C., Bièche, Ivan, Kristel, Petra, Ibadioune, Sabrina, Eeckhoutte, Alexandre, de Bruijn, Roebi, van der Burg, Eline, Lutz, Catrin, Annunziato, Stefano, de Ruiter, Julian, Masliah Planchon, Julien, Vacher, Sophie, Courtois, Laura, El-Botty, Rania, Dahmani, Ahmed, Montaudon, Elodie, Morisset, Ludivine, Sourd, Laura, Huguet, Léa, Derrien, Heloise, Nemati, Fariba, Chateau-Joubert, Sophie, Larcher, Thibaut, Salomon, Anne, Decaudin, Didier, Reyal, Fabien, Coussy, Florence, Popova, Tatiana, Wesseling, Jelle, Stern, Marc-Henri, Jonkers, Jos, and Marangoni, Elisabetta

Published
2023
Full Text
View/download PDF

10. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.

Author

Yau, Christina, Osdoit, Marie, van der Noordaa, Marieke, Shad, Sonal, Wei, Jane, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, Martín, Miguel, Del Monte-Millán, Maria, López-Tarruella, Sara, I-SPY 2 Trial Consortium, Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, Edge, Stephen B, Abraham, Jean E, Bartlett, John MS, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, Thomas, Jeremy S, Cameron, David, Graham, Ashley, Hall, Peter, Mackintosh, Lorna, Fan, Fang, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Pusztai, Lajos, Kim, Mi-Ok, van 't Veer, Laura J, Esserman, Laura J, and Symmans, W Fraser

Subjects
I-SPY 2 Trial Consortium, Humans, Breast Neoplasms, Neoplasm, Residual, Receptor, erbB-2, Chemotherapy, Adjuvant, Neoadjuvant Therapy, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Young Adult, Receptor, ErbB-2, Breast Cancer, Patient Safety, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the relationship of RCB with long-term prognosis across different phenotypic subtypes of breast cancer, to assess generalisability in a broad range of practice settings.MethodsIn this pooled analysis, 12 institutes and trials in Europe and the USA were identified by personal communications with site investigators. We obtained participant-level RCB results, and data on clinical and pathological stage, tumour subtype and grade, and treatment and follow-up in November, 2019, from patients (aged ≥18 years) with primary stage I-III breast cancer treated with neoadjuvant chemotherapy followed by surgery. We assessed the association between the continuous RCB score and the primary study outcome, event-free survival, using mixed-effects Cox models with the incorporation of random RCB and cohort effects to account for between-study heterogeneity, and stratification to account for differences in baseline hazard across cancer subtypes defined by hormone receptor status and HER2 status. The association was further evaluated within each breast cancer subtype in multivariable analyses incorporating random RCB and cohort effects and adjustments for age and pretreatment clinical T category, nodal status, and tumour grade. Kaplan-Meier estimates of event-free survival at 3, 5, and 10 years were computed for each RCB class within each subtype.FindingsWe analysed participant-level data from 5161 patients treated with neoadjuvant chemotherapy between Sept 12, 1994, and Feb 11, 2019. Median age was 49 years (IQR 20-80). 1164 event-free survival events occurred during follow-up (median follow-up 56 months [IQR 0-186]). RCB score was prognostic within each breast cancer subtype, with higher RCB score significantly associated with worse event-free survival. The univariable hazard ratio (HR) associated with one unit increase in RCB ranged from 1·55 (95% CI 1·41-1·71) for hormone receptor-positive, HER2-negative patients to 2·16 (1·79-2·61) for the hormone receptor-negative, HER2-positive group (with or without HER2-targeted therapy; p

Published
2022

12. Evolution of synchronous female bilateral breast cancers and response to treatment

Author

Hamy, Anne-Sophie, Abécassis, Judith, Driouch, Keltouma, Darrigues, Lauren, Vandenbogaert, Mathias, Laurent, Cecile, Zaccarini, Francois, Sadacca, Benjamin, Delomenie, Myriam, Laas, Enora, Mariani, Odette, Lam, Thanh, Grandal, Beatriz, Laé, Marick, Bieche, Ivan, Vacher, Sophie, Pierga, Jean-Yves, Brain, Etienne, Vallot, Celine, Hotton, Judicael, Richer, Wilfrid, Rocha, Dario, Tariq, Zakia, Becette, Veronique, Meseure, Didier, Lesage, Laetitia, Vincent-Salomon, Anne, Filmann, Natalie, Furlanetto, Jenny, Loibl, Sibylle, Dumas, Elise, Waterfall, Joshua J., and Reyal, Fabien

Published
2023
Full Text
View/download PDF

15. Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer

Author

Van Baelen, Karen, Nguyen, Ha-Linh, Hamy-Petit, Anne-Sophie, Richard, François, Karsten, Maria Margarete, Nader Marta, Guilherme, Vermeulen, Peter, Toussaint, Aullene, Reyal, Fabien, Vincent-Salomon, Anne, Dirix, Luc, Dordevic, Adam David, de Azambuja, Evandro, Larsimont, Denis, Amato, Ottavia, Maetens, Marion, De Schepper, Maxim, Geukens, Tatjana, Han, Sileny N., Baert, Thaïs, Punie, Kevin, Wildiers, Hans, Smeets, Ann, Nevelsteen, Ines, Floris, Giuseppe, Biganzoli, Elia, Neven, Patrick, and Desmedt, Christine

Published
2023
Full Text
View/download PDF

18. Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.

Author

Laas, Enora, primary, Hamy, Anne-Sophie, additional, Bachelot, Thomas, additional, Lemonnier, Jerome, additional, Andre, Fabrice, additional, Cameron, David A., additional, Bliss, Judith, additional, Chabaud, Sylvie, additional, Hardy-Bessard, Anne-Claire, additional, Lacroix-Triki, Magali, additional, Debled, Marc, additional, Campone, Mario, additional, Cottu, Paul H., additional, Dalenc, Florence, additional, Tredan, Olivier, additional, Penault-Llorca, Frederique Madeleine, additional, Asselain, Bernard, additional, Reyal, Fabien, additional, Levi, Francis, additional, and Giacchetti, Sylvie, additional

Published
2024
Full Text
View/download PDF

20. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study

Author

Houvenaeghel, Gilles, de Nonneville, Alexandre, Cohen, Monique, Classe, Jean-Marc, Reyal, Fabien, Mazouni, Chafika, Faure, Christelle, Martinez, Alejandra, Chauvet, Marie-Pierre, Daraï, Emile, Coutant, Charles, Colombo, Pierre-Emmanuel, Gimbergues, Pierre, Azuar, Anne-Sophie, Rouzier, Roman, Tunon de Lara, Christine, Crochet, Patrice, Rua, Sandrine, and Gonçalves, Anthony

Published
2022
Full Text
View/download PDF

24. Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial

Author

Delrieu, Lidia, Hamy, Anne-Sophie, Coussy, Florence, Kassara, Amyn, Asselain, Bernard, Antero, Juliana, De Villèle, Paul, Dumas, Elise, Forstmann, Nicolas, Guérin, Julien, Hotton, Judicael, Jouannaud, Christelle, Milder, Maud, Leopold, Armand, Sedeaud, Adrien, Soibinet, Pauline, Toussaint, Jean-François, Vercamer, Vincent, Laas, Enora, and Reyal, Fabien

Published
2022
Full Text
View/download PDF

26. Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery.

Author

Houvenaeghel, Gilles, Classe, Jean-Marc, Chauvet, Marie-Pierre, Colombo, Pierre-Emmanuel, Jouve, Eva, Reyal, Fabien, Daraï, Emile, Rouzier, Roman, Faure-Virelizier, Christelle, Gimbergues, Pierre, Coutant, Charles, Mazouni, Chafika, Azuar, Anne-Sophie, Martino, Marc, Bouteille, Catherine, Cohen, Monique, and de Nonneville, Alexandre

Subjects
BREAST cancer prognosis, BREAST tumors, PROTEIN-tyrosine kinase inhibitors, AGE distribution, RETROSPECTIVE studies, TUMOR grading, ADJUVANT chemotherapy, ONCOGENES, HORMONE therapy, MEDICAL records, ACQUISITION of data, CYCLIN-dependent kinases, LUMPECTOMY, CHEMICAL inhibitors
Abstract

Simple Summary: Improved outcomes have been reported with adjuvant treatment combining cyclin-dependent kinase 4/6 inhibitors with endocrine therapy, in high-risk patients with ER-positive and HER2-negative breast cancer, regardless of age. In this real-world data analysis, MonarchE and NataLEE high-risk patients accounted for 9.5% and 33% of patients undergoing upfront surgery, respectively. Significantly higher eligibility rates were observed in patients who underwent a mastectomy, >70 years and ≤40 years for adjuvant abemaciclib and ribociclib, and in patients >80 years for ribociclib. A higher discontinuation rate for abemaciclib was reported in patients ≥65 years and it can be assumed that discontinuation rates may increase with more older patients. If the results of the NataLEE trial translate into clinical practice, the number of patients potentially eligible for adjuvant CDK4/6 inhibitors may increase, especially in the elderly population. Background: Despite early diagnosis, approximately 20% of patients with ER-positive and HER2-negative breast cancer (BC) will experience disease recurrence. Improved survival has been reported with adjuvant treatment combining cyclin-dependent kinase 4/6 inhibitors with endocrine therapy, in high-risk patients with ER-positive and HER2-negative BC, regardless of age. Older patients have higher rates of ER-positive/HER2-negative BC than younger patients. Methods: In this real-world data analysis, MonarchE and NataLEE high-risk patients accounted for 9.5% and 33% of patients undergoing upfront surgery, respectively. Significantly higher eligibility rates were observed in patients who underwent a mastectomy, >70 years and ≤40 years for adjuvant abemaciclib and ribociclib, and in patients >80 years for ribociclib. Results: Eligibility rates in patients ≤40 years and >80 years who underwent mastectomy were 27.8% and 24.7% for abemaciclib, respectively, and 56.6% and 65.2% for ribociclib, respectively. A higher discontinuation rate for abemaciclib was reported in patients aged ≥65 years and it can be assumed that discontinuation rates may increase in even older patients. Conclusions: If the results of the NataLEE trial translate into clinical practice, the number of patients potentially eligible for adjuvant CDK4/6 inhibitors may increase, especially in the elderly population. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Author

Adamson, Kathi, Albain, Kathy S., Asare, Adam L., Asare, Smita M., Balassanian, Ron, Beckwith, Heather, Berry, Scott M., Berry, Donald A., Boughey, Judy C., Buxton, Meredith B., Chen, Yunn-Yi, Chen, Beiyun, Chien, A. Jo, Chui, Stephen Y., Clark, Amy S., Clennell, Julia L., Datnow, Brian, DeMichele, Angela M., Duan, Xiuzhen, Edmiston, Kirsten K., Elias, Anthony D., Ellis, Erin D., Esserman, Laura L., Euhus, David M., Fadare, Oluwole, Fan, Fang, Feldman, Michael D, Forero-Torres, Andres, Haley, Barbara B., Han, Hyo S., Harada, Shuko, Haugen, Patricia, Helsten, Teresa, Hirst, Gillian L., Hylton, Nola M., Isaacs, Claudine, Kemmer, Kathleen, Khan, Qamar J., Khazai, Laila, Klein, Molly E., Krings, Gregor, Lang, Julie E., LeBeau, Lauren G., Leyland-Jones, Brian, Liu, Minetta C., Lo, Shelly, Lu, Janice, Magliocco, Anthony, Matthews, Jeffrey B., Melisko, Michelle E., Mhawech-Fauceglia, Paulette, Moulder, Stacy L., Murthy, Rashmi K., Nanda, Rita, Northfelt, Donald W., Ocal, Idris T., Olopade, Olufunmilayo, Pambuccian, Stefan, Paoloni, Melissa, Park, John W., Parker, Barbara A., Perlmutter, Jane, Peterson, Garry, Pusztai, Lajos, Rendi, Mara, Rugo, Hope S., Sahoo, Sunati, Sams, Sharon, Sanil, Ashish, Sattar, Husain, Schwab, Richard B., Singhrao, Ruby, Steeg, Katherine, Stringer-Reasor, Erica, Symmans, W. Fraser, Tawfik, Ossama, Tripathy, Debasish, Troxell, Megan L., van't Veer, Laura J., Venters, Sara J., Vinh, Tuyethoa, Viscusi, Rebecca K., Wallace, Anne M., Wei, Shi, Wilson, Amy, Yau, Christina, Yee, Douglas, Zeck, Jay C., Osdoit, Marie, van der Noordaa, Marieke, Shad, Sonal, Wei, Jane, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, Martín, Miguel, del Monte-Millán, Maria, López-Tarruella, Sara, Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, Edge, Stephen B, Abraham, Jean E, Bartlett, John M S, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, Thomas, Jeremy S, Cameron, David, Graham, Ashley, Hall, Peter, Mackintosh, Lorna, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Kim, Mi-Ok, van 't Veer, Laura J, Esserman, Laura J, and Symmans, W Fraser

Published
2022
Full Text
View/download PDF

28. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns

Author

Gougis, Paul, primary, Hamy, Anne-Sophie, additional, Jochum, Floriane, additional, Bihan, Kevin, additional, Carbonnel, Marie, additional, Salem, Joe-Elie, additional, Dumas, Elise, additional, Kabirian, Rayan, additional, Grandal, Beatriz, additional, Barraud, Solenn, additional, Coussy, Florence, additional, Hotton, Judicael, additional, Savarino, Raphaelle, additional, Marabelle, Aurélien, additional, Cadranel, Jacques, additional, Spano, Jean-Philippe, additional, Laas, Enora, additional, Reyal, Fabien, additional, and Abbar, Baptiste, additional

Published
2024
Full Text
View/download PDF

29. Superior Pedicle Oncoplasty

Author

Reyal, Fabien, Laas, Enora, Aubry, Gabrielle, Labrosse, Julie, Bout-Roumazeilles, Apolline, Sabaila, Anne, Rossi, Léa, Feron, Jean-Guillaume, Binder, Jean-Philippe, Couturaud, Benoit, Klimberg, V. Suzanne, editor, Kovacs, Tibor, editor, and Rubio, Isabel T., editor

Published
2020
Full Text
View/download PDF

30. Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance

Author

Lodillinsky, Catalina, Fuhrmann, Laetitia, Irondelle, Marie, Pylypenko, Olena, Li, Xiao-Yan, Bonsang-Kitzis, Hélène, Reyal, Fabien, Vacher, Sophie, Calmel, Claire, De Wever, Olivier, Bièche, Ivan, Lacombe, Marie-Lise, Eiján, Ana Maria, Houdusse, Anne, Vincent-Salomon, Anne, Weiss, Stephen J., Chavrier, Philippe, and Boissan, Mathieu

Published
2021
Full Text
View/download PDF

32. Automatic deep learning method for third lumbar selection and body composition evaluation on CT scans of cancer patients.

Author

Delrieu, Lidia, Blanc, Damien, Bouhamama, Amine, Reyal, Fabien, Pilleul, Frank, Racine, Victor, Hamy, Anne Sophie, Crochet, Hugo, Marchal, Timothée, and Heudel, Pierre Etienne

Subjects
ABDOMINAL muscles, ADIPOSE tissues, BODY mass index, LEANNESS, COMPUTED tomography, BODY composition, BODY weight, DESCRIPTIVE statistics, CANCER patients, METASTASIS, LUMBAR vertebrae, DEEP learning, DIGITAL image processing, SARCOPENIA, ALGORITHMS, OBESITY
Abstract

Introduction: The importance of body composition and sarcopenia is wellrecognized in cancer patient outcomes and treatment tolerance, yet routine evaluations are rare due to their time-intensive nature. While CT scans provide accurate measurements, they depend on manual processes. We developed and validated a deep learning algorithm to automatically select and segment abdominal muscles [SM], visceral fat [VAT], and subcutaneous fat [SAT] on CT scans. Materials and Methods: A total of 352 CT scans were collected from two cancer centers. The detection of the third lumbar vertebra and three different body tissues (SM, VAT, and SAT) were annotated manually. The 5-fold cross-validation method was used to develop the algorithm and validate its performance on the training cohort. The results were validated on an external, independent group of CT scans. Results: The algorithm for automatic L3 slice selection had a mean absolute error of 4 mm for the internal validation dataset and 5.5 mm for the external validation dataset. The median DICE similarity coefficient for body composition was 0.94 for SM, 0.93 for VAT, and 0.86 for SAT in the internal validation dataset, whereas it was 0.93 for SM, 0.93 for VAT, and 0.85 for SAT in the external validation dataset. There were high correlation scores with sarcopenia metrics in both internal and external validation datasets. Conclusions: Our deep learning algorithm facilitates routine research use and could be integrated into electronic patient records, enhancing care through better monitoring and the incorporation of targeted supportive measures like exercise and nutrition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Theoretical and practical knowledge curriculum for European Breast Surgeons

Author

Benn, Karen, Cardoso, Maria Joao, Catanuto, Giuseppe, Costa, Alberto, Curigliano, Giuseppe, Cserni, Gabor, Downey, Sarah, Farhadi, Jian, Gentilini, Oreste, Gulluoglu, Bahadir, Herrero, Julia Camps, Karakatsanis, Andreas, Knauer, Michael, Kolacinska, Agnieszka, Leidenius, Marjut, McNeill, Fiona, Müseler, Shirley Bianca L., Poortmanns, Philip, Reyal, Fabien, Sandelin, Kerstin, Morgan, Jenna, Montagna, Giacomo, Wandschneider, Wiebke, Kovacs, Tibor, Rubio, Isabel T., Markopoulos, Christos, Audisio, Riccardo A., Knox, Susan, Kühn, Thorsten, Mansel, Robert, Matrai, Zoltan, Meani, Francesco, Nava, Maurizio, and Wyld, Lynda

Published
2020
Full Text
View/download PDF

38. Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial

Author

De Caluwé, Alex, Buisseret, Laurence, Poortmans, Philip, Van Gestel, Dirk, Salgado, Roberto, Sotiriou, Christos, Larsimont, Denis, Paesmans, Marianne, Craciun, Ligia, Stylianos, Drisis, Vandekerckhove, Christophe, Reyal, Fabien, Isabelle, Veys, Eiger, Daniel, Piccart, Martine, Romano, Emanuela, and Ignatiadis, Michail

Published
2021
Full Text
View/download PDF

40. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns

Author

Gougis, Paul, primary, Grandal, Beatriz, additional, Jochum, Floriane, additional, Bihan, Kevin, additional, Coussy, Florence, additional, Barraud, Solenn, additional, Asselain, Bernard, additional, Dumas, Elise, additional, Sebbag, Clara, additional, Hotton, Judicael, additional, Spaggiari, Emmanuel, additional, Pierga, Jean-Yves, additional, Savarino, Raphaëlle, additional, Laas, Enora, additional, Spano, Jean-Philippe, additional, Reyal, Fabien, additional, and Hamy, Anne-Sophie, additional

Published
2023
Full Text
View/download PDF

42. Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery

Author

Houvenaeghel, Gilles, primary, Cohen, Monique, additional, Martino, Marc, additional, Reyal, Fabien, additional, Classe, Jean-Marc, additional, Chauvet, Marie-Pierre, additional, Colombo, Pierre-Emmanuel, additional, Heinemann, Mellie, additional, Jouve, Eva, additional, Gimbergues, Pierre, additional, Azuar, Anne-Sophie, additional, Coutant, Charles, additional, Gonçalves, Anthony, additional, and de Nonneville, Alexandre, additional

Published
2023
Full Text
View/download PDF

43. Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression

Author

Romero, Pierre, Benhamo, Vanessa, Deniziaut, Gabrielle, Fuhrmann, Laetitia, Berger, Frédérique, Manié, Elodie, Bhalshankar, Jaydutt, Vacher, Sophie, Laurent, Cécile, Marangoni, Elisabetta, Gruel, Nadège, MacGrogan, Gaëtan, Rouzier, Roman, Delattre, Olivier, Popova, Tatiana, Reyal, Fabien, Stern, Marc-Henri, Stoppa-Lyonnet, Dominique, Marchiò, Caterina, Bièche, Ivan, and Vincent-Salomon, Anne

Published
2018
Full Text
View/download PDF

44. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit

Author

de Nonneville, Alexandre, Jauffret, Camille, Gonçalves, Anthony, Classe, Jean-Marc, Cohen, Monique, Reyal, Fabien, Mazouni, Chafika, Chauvet, Marie-Pierre, Chopin, Nicolas, Colombo, Pierre-Emmanuel, Jouve, Eva, Darai, Emile, Rouzier, Roman, Coutant, Charles, Gimbergues, Pierre, Azuar, Anne-Sophie, de Lara, Christine Tunon, Lambaudie, Eric, and Houvenaeghel, Gilles

Published
2019
Full Text
View/download PDF

46. Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact

Author

Houvenaeghel, Gilles, de Nonneville, Alexandre, Cohen, Monique, Classe, Jean-Marc, Reyal, Fabien, Mazouni, Chafika, Chopin, Nicolas, Martinez, Alejandra, Daraï, Emile, Coutant, Charles, Colombo, Pierre-Emmanuel, Gimbergues, Pierre, Chauvet, Marie-Pierre, Azuar, Anne-Sophie, Rouzier, Roman, de Lara, Christine Tunon, Muracciole, Xavier, Agostini, Aubert, Gonçalves, Anthony, and Lambaudie, Eric

Published
2019
Full Text
View/download PDF

48. Sentinel lymph node biopsy validation for large tumors

Author

Houvenaeghel, Gilles, Quilichini, Olivia, Cohen, Monique, Reyal, Fabien, Classe, Jean-Marc, Mazouni, Chafika, Giard, Sylvie, Carrabin, Nicolas, Charitansky, Hélène, Darai, Emile, Hudry, Delphine, Azuar, Pierre, Villet, Richard, Gimbergues, Pierre, Tunon-DE-Lara, Christine, and Lambaudie, Eric

Published
2017
Full Text
View/download PDF

50. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer

Author

Reyal, Fabien, van Vliet, Martin H, Armstrong, Nicola J, Horlings, Hugo M, de Visser, Karin E, Kok, Marlen, Teschendorff, Andrew E, Mook, Stella, van 't Veer, Laura, Caldas, Carlos, Salmon, Remy J, Vijver, Marc J van de, and Wessels, Lodewyk FA

Subjects
Genetics, Cancer, Breast Cancer, Human Genome, Breast Neoplasms, Cell Proliferation, Computational Biology, Databases, Genetic, Female, Gene Expression Profiling, Humans, Immune System Phenomena, Prognosis, RNA Splicing, Survival Rate, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

IntroductionSeveral gene expression signatures have been proposed and demonstrated to be predictive of outcome in breast cancer. In the present article we address the following issues: Do these signatures perform similarly? Are there (common) molecular processes reported by these signatures? Can better prognostic predictors be constructed based on these identified molecular processes?MethodsWe performed a comprehensive analysis of the performance of nine gene expression signatures on seven different breast cancer datasets. To better characterize the functional processes associated with these signatures, we enlarged each signature by including all probes with a significant correlation to at least one of the genes in the original signature. The enrichment of functional groups was assessed using four ontology databases.ResultsThe classification performance of the nine gene expression signatures is very similar in terms of assigning a sample to either a poor outcome group or a good outcome group. Nevertheless the concordance in classification at the sample level is low, with only 50% of the breast cancer samples classified in the same outcome group by all classifiers. The predictive accuracy decreases with the number of poor outcome assignments given to a sample. The best classification performance was obtained for the group of patients with only good outcome assignments. Enrichment analysis of the enlarged signatures revealed 11 functional modules with prognostic ability. The combination of the RNA-splicing and immune modules resulted in a classifier with high prognostic performance on an independent validation set.ConclusionsThe study revealed that the nine signatures perform similarly but exhibit a large degree of discordance in prognostic group assignment. Functional analyses indicate that proliferation is a common cellular process, but that other functional categories are also enriched and show independent prognostic ability. We provide new evidence of the potentially promising prognostic impact of immunity and RNA-splicing processes in breast cancer.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results